Heart Failure Burden by Autopsy, Guideline-Directed Medical Therapy, and ICD Utilization Among Sudden Deaths

Satvik Ramakrishna1, James W Salazar2, Jeffrey E Olgin2

  • 1Division of Cardiovascular Medicine, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.

Insights

Nearly 20% of sudden cardiac deaths involve heart failure (HF). Most HF-related sudden deaths are arrhythmic, yet guideline-directed medical therapy (GDMT) and implantable cardioverter-defibrillator (ICD) use remain low, highlighting key prevention targets.

Area of Science:

  • Cardiology
  • Forensic Pathology
  • Public Health

Background:

  • Sudden cardiac death (SCD) is a significant concern in heart failure (HF), particularly in heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF).
  • However, the underlying causes of SCD in HF patients within the community, as well as the utilization of guideline-directed medical therapy (GDMT) and implantable cardioverter-defibrillators (ICDs), remain largely uncharacterized.

Purpose of the Study:

  • To investigate the prevalence of HF in autopsied SCD cases.
  • To determine the proportion of sudden arrhythmic deaths (SADs) in HF patients.
  • To assess the use of GDMT and ICDs in HF patients who experienced SCD.

Main Methods:

  • A countywide postmortem study (POST SCD) examined all presumed SCDs in San Francisco County from 2011-2014.
  • Autopsies were performed on individuals aged 18-90 years with incident WHO-defined presumed SCDs.
  • Sudden arrhythmic deaths (SADs) were defined as those without an identifiable nonarrhythmic cause, suggesting potential benefit from ICD therapy.

Main Results:

  • Heart failure was present in 19% (100 of 525) of presumed SCDs, including 85 patients with known HF and 15 with subclinical HF.
  • Sudden arrhythmic deaths (SADs) accounted for 69% of HF-related SCDs, with similar rates in HFrEF (74%) and HFpEF (61%).
  • Only 4% of SAD patients had an ICD, and complete GDMT use in HFrEF was only 6%.

Conclusions:

  • Heart failure is a significant contributor to community sudden cardiac deaths, with a majority of these being potentially preventable arrhythmic events.
  • Current utilization of ICDs and GDMT in HF patients experiencing SCD is critically low, indicating substantial room for improvement in sudden death prevention strategies.
  • There is a need to optimize the identification and treatment of HF patients at risk for SCD to reduce mortality from these events.
Abstract

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
22
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
15
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
22
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
21
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
31